This secondary analysis of a phase 3 randomized clinical trial investigates the role of tumor-infiltrating lymphocytes in predicting outcomes in patients with HER2-positive metastatic breast cancer randomized to antibody vs small molecule–based anti-HER2 therapy.
http://ift.tt/2vMs7rw
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου